‘Tivo’ off screen: Astellas ending Aveo VEGF deal after failure reruns
Steadily declining hopes for tivozanib, the tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptors, hit bottom with Astellas Pharma Inc.’s decision to quit its deal with Aveo Oncology Inc., which brought $125 million up front in 2011 and the promise of more than $1 billion in potential milestone payments.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter